NCT00372775 - Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Sunitinib

Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity

Trial Locations (27)

10022

Pfizer Investigational Site, New York

10043

Pfizer Investigational Site, Orbassano (TO)

11725

Pfizer Investigational Site, Commack

13009

Pfizer Investigational Site, Marseille

16132

Pfizer Investigational Site, Genova

18840

Pfizer Investigational Site, Sayre

28046

Pfizer Investigational Site, Madrid

31059

Pfizer Investigational Site, Toulouse

32796

Pfizer Investigational Site, Titusville

32931

Pfizer Investigational Site, Cocoa Beach

32952

Pfizer Investigational Site, Merritt Island

33604

Pfizer Investigational Site, Pessac

40139

Pfizer Investigational Site, Bologna

42271

Pfizer Investigational Site, Saint-Priest-en-Jarez

46014

Pfizer Investigational Site, Valencia

63110

Pfizer Investigational Site, St Louis

63141

Pfizer Investigational Site, Creve Coeur

63376

Pfizer Investigational Site, City of Saint Peters

78664

Pfizer Investigational Site, Round Rock

78705

Pfizer Investigational Site, Austin

78745

Pfizer Investigational Site, Austin

78758

Pfizer Investigational Site, Austin

78759

Pfizer Investigational Site, Austin

06856

Pfizer Investigational Site, Norwalk

63110-1094

Pfizer Investigational Site, St Louis

07920

Pfizer Investigational Site, Basking Ridge

00151

Pfizer Investigational Site, Roma